    Debora Jorn | VIVEVE MEDICAL, INC. | ZoomInfo.com    Deborah Jorn | Bausch & Lomb Incorporated | ZoomInfo.com










 





Insider Trading - Jorn Debora - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Jorn Debora





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-12-23Option Award
2016-12-289:00 pm
N/A2026-12-22
Viveve Medical Inc
VIVE
Jorn DeboraDirector
25,160
$5.22
25,160(Direct)
View


2016-11-09Option Award
2016-11-144:03 pm
N/AN/A
Viveve Medical Inc
VIVE
Jorn DeboraDirector
1,109
$0
1,909(Direct)
View


2016-11-02Option Award
2016-11-042:21 pm
N/A2026-11-02
Psivida Corp.
PSDV
Jorn DeboraEVP, Corp. & Comm'l Dev.
300,000
$1.91
300,000(Direct)
View


2016-08-22Option Award
2016-08-248:56 pm
N/AN/A
Viveve Medical Inc
VIVE
Jorn DeboraDirector
800
$0
4,590(Direct)
View


2016-08-22Option Award
2016-08-248:56 pm
N/A2026-08-22
Viveve Medical Inc
VIVE
Jorn DeboraDirector
4,590
$7.89
4,590(Direct)
View


2016-07-12Option Award
2016-07-141:27 pm
N/A2026-07-11
Orexigen Therapeutics Inc.
OREX
Jorn DeboraDirector
16,500
$4.02
16,500(Direct)
View


2016-05-20Option Award
2016-05-242:25 pm
N/A2026-05-19
Orexigen Therapeutics Inc.
OREX
Jorn DeboraDirector
70,000
$0.4
70,000(Direct)
View


2016-05-11Option Award
2016-05-203:57 pm
N/A2026-05-11
Viveve Medical Inc
VIVMF
Jorn DeboraDirector
5,250
$7.74
5,250(Direct)
View


2015-11-20Tax Withholding
2015-11-244:20 pm
N/AN/A
Valeant Pharmaceuticals International Inc.
VRX
Jorn DeboraEVP, Company Group Chairman
1,370
$0
34,812(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Sat, 29 Jul 2017 02:34:20 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








Stock Screener - Yahoo FinanceHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreYahooSearchSearch0U.S. Markets closedS&P 5002,472.10-3.32 (-0.13%)Dow 3021,830.31+33.76 (+0.15%)LISTENWho is the face of pro baseball?Yahoo Finance's Dan Roberts and Myles Udland debate the business of baseballInsider TransactionsDefault CriteriaInsider & Restricted Shareholder Transactions1-4 of 4 resultsResults were generated a few mins ago. Pricing data is updated frequently. Currency in USDSymbolDateSharesProceedsTransaction DetailsVIVE2017-05-16686N/AAcquisition (Non Open Market) at $0.00 per share.VIVE2016-11-081,109N/AAcquisition (Non Open Market) at $0.00 per share.VIVE2016-08-21800N/AAcquisition (Non Open Market) at $0.00 per share.VRX2015-11-191,370N/ADisposition (Non Open Market) at $0.00 per share.Anthony Scaramucci's wife reportedly filed for divorce because he was 'hell-bent' on joining TrumpBusiness InsiderSolar Eclipse 2017: Stay in the Tualatin ValleyThe Tualatin ValleySponsoredMainstream Model 3 holds promise _ and peril _ for TeslaAssociated PressYahoo Small BusinessData DisclaimerHelpSuggestionsPrivacyAbout Our AdsTerms (Updated)






Deborah Jorn Profiles | Facebook

FacebookEmail or PhonePasswordForgot account?English (US)EspañolFrançais (France)中文(简体)العربيةPortuguês (Brasil)Italiano한국어Deutschहिन्दी日本語MessengerFacebook LitePeoplePlacesGamesLocationsCelebritiesMarketplaceGroupsRecipesMomentsInstagramAboutCreate AdCreate PageDevelopersCareersPrivacyCookiesAd ChoicesTermsSettingsActivity Log Facebook © 2017


















 

Viveve Medical Inc (VIVE.O)  People | Reuters.com


























































X



Edition:

United States


















Africa
América Latina


عربي
Argentina


Brasil
Canada


中国
Deutschland


España
France


India
Italia


日本
México


РОССИЯ
United Kingdom

United States
















Viveve Medical Inc (VIVE.O)










Related Topics: 
StocksStock ScreenerMarket DataHealthcareAdvanced Medical Equipment & Technology












                
                        Overview
                    



                
                        News
                    



                
                        Key Developments
                    



                
                        People
                    



                
                        Charts
                    



                
                        Financials
                    



                
                        Analysts
                    



                    
                            Research
                        



                    
                            Pulse
                        










				VIVE.O on Consolidated Issue listed on NASDAQ Capital Market


				6.70USD
28 Jul 2017





				    Change	(% chg)


		    
						    $0.02


					            (+0.30%)
					        






Prev Close

$6.68


Open

$6.67




Day's High

$6.91


Day's Low

$6.67




Volume

88,906


Avg. Vol

241,377




52-wk High

$11.16


52-wk Low

$3.75











					Summary





Name
Age
Since
Current Position




							James Atkinson

57
2015

                                Chief Business Officer and President




							Patricia Scheller

55
2014

                                Chief Executive Officer, Director




							Scott Durbin

46
2013

                                Chief Financial Officer




							Alan Curtis


2014

                                Vice President - Regulatory, Clinical and Quality




							Steve Lopez


2014

                                Director - Operations




							Lori Bush

59
2016

                                Director




							Debora Jorn

59
2016

                                Director




							Arlene Morris

65
2016

                                Director




							Jon Plexico

48
2016

                                Director




							Daniel Janney

51
2014

                                Independent Director



» Insider Trading





					Biographies





Name
Description




							James Atkinson


					
							Mr. James G. Atkinson is Chief Business Officer and President of Viveve Medical, Inc. Prior to joining Viveve as Chief Business Officer and President, Jim was the Senior Vice President of Global Sales at Ulthera, Inc. through April, 2014. He was the third employee to join the company in October, 2006 as Senior Vice President of Sales and Marketing. While at Ulthera, he helped grow the company from 3 to 165 employees and established a global distribution network that included 42 distributors, covering 52 countries. Ulthera was purchased by Merz Aesthetics for $600 million in 2014. Before joining Ulthera, Mr. Atkinson served as Vice President of Sales and Marketing for the Cardiac Surgery Division at St. Jude Medical, where his responsibilities included launching the Biocor stented tissue valve, recognized as the fastest growing heart valve brand in the industry. Prior to St. Jude Medical, he served as Vice President of Sales for Medtronic Vascular, a $200 million division of Medtronic, Inc. Mr. Atkinson's entrepreneurial spirit led him to co-found and serve as Vice President of Sales and Business Development for Medical Simulation Corporation, the leading developer of state-of-the-art simulation technologies and services for the cardiology, cardiac surgery and nursing industries. His career began as a sales representative at Ethicon Endosurgery where he progressed through positions of increasing responsibility to Regional V.




							Patricia Scheller


					
							Ms. Patricia K. Scheller is Chief Executive Officer, Director of Viveve Medical, Inc. Ms. Scheller was elected as a director of Viveve Medical, Inc. on September 18, 2014 (with her service beginning following the Merger) and has been a director of our wholly-owned subsidiary, Viveve, Inc., since June 2012. Ms. Scheller also serves as our Chief Executive Officer and, since May 2012, as Chief Executive Officer of Viveve, Inc. Prior to joining Viveve, Inc., she served as the Chief Executive Officer of Prescient Medical, Inc. (“PMI”), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks, from September 2004 through April 2012 and as a director of PMI from July 2004 to September 2011. Prior to joining PMI, from August 2003 to September 2004, she was the Chief Executive Officer of SomaLogic, a biotechnology company focused on the development of diagnostic products using aptamer technology. From December 2000 to April 2003, Ms. Scheller also managed several business units at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and from October 1997 to November 2000 served in key executive positions at Dade Behring, a clinical diagnostics firm. While at Dade Behring Holdings, Inc., she directed the commercialization of the hsCRP diagnostic test, a screening test for systemic inflammation, which has been shown to increase the risk of heart attacks. The hsCRP test was the first diagnostic test added to the cardiac test panel by the Centers for Disease Control and Prevention and the American Heart Association in over 30 years.




							Scott Durbin


					
							Mr. Scott C. Durbin is Chief Financial Officer of Viveve Medical, Inc. Mr. Durbin joined Viveve, Inc. as its Chief Financial Officer in February 2013 and was appointed as the Chief Financial Officer of Viveve Medical, Inc. on September 23, 2014. From June 2012 to January 2013 he served as an advisor and Acting Chief Financial Officer for Viveve, Inc. Prior to joining Viveve, Inc., from June 2010 to October 2011, he was Chief Financial Officer of Aastrom Biosciences (“Aastrom”), a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years as Chief Operating and Financial Officer for Prescient Medical (“Prescient”) from May 2004 to June 2010, a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to Prescient, from January 2003 to April 2004, he spent several years as a financial consultant for two publicly traded biotech companies, Scios Inc. – a Johnson & Johnson company and Alteon Inc. Mr. Durbin began his career in corporate finance as an investment banker in the Healthcare and M&A groups at Lehman Brothers Inc. from August 1999 to January 2003, where he focused on mergers and acquisitions and financings for the life science industry. At Lehman, he successfully executed over $5 billion in transactions for medical device and biotechnology companies. He began his career as a Director of Neurophysiology for Biotronic, Inc. Mr. Durbin received a B.S. from the University of Michigan and an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.




							Alan Curtis


					
							Mr. Alan Curtis is Vice President - Regulatory, Clinical and Quality of Viveve Medical, Inc. He joined Viveve in January 2010. In his role as Vice President of Regulatory, Clinical and Quality, Alan brings over 30 years of experience to the organization. Alan has been involved in many medical device start-ups including Aragon Surgical, Reliant Technologies, SURx, and Endosonics. Alan also gained PMA approval for an interventional cardiology device while with W.L. Gore and Associates. He has created and implemented robust Quality Systems to meet domestic and international regulatory requirements. In addition, Alan has established successful clinical and regulatory strategies that led to device commercialization in the U.S. as well as CE Mark for international distribution. Alan is a member of the Regulatory Affairs Professionals Society and is certified as an RAC. Alan attended California State University and received a B.Sc. in Microbiology.




							Steve Lopez


					
							Mr. Steve Lopez is Director of Operations of Viveve Medical, Inc. Steve joined Viveve in April 2009. He brings over 20 years of engineering, manufacturing, quality and operational experience supporting asthma, cardiovascular, esophageal, oncology, and surgical products, both in early stage and Fortune 500 companies. More recently, Steve worked at Asthmatx (now Boston Scientific) as the Director of Operations where he led the transition from R&D assembly into clinical manufacturing along with managing scale-up activities for commercial release. Steve has held various leadership and technical roles at BÂRRX Medical (now Covidien), Boston Scientific, RadioTherapeutics (now Boston Scientific), Johnson & Johnson, and Guidant (now Abbott Vascular). Steve earned his M.S. degree in Engineering Management from California State University, Northridge, received his B.S. degree in Engineering from California State Polytechnic University, Pomona, and is a Certified Manufacturing Engineer.




							Lori Bush


					
							Ms. Lori H Bush is Director of the Company. She has over 30 years of experience in the consumer and healthcare products industries with a proven track record in building highly successful brands. Most recently, she served as president and chief executive officer of Rodan + Fields, a premium skincare company that grew from a start-up to over $600M in revenue during her 8 year tenure with the company. Ms. Bush's previous executive roles include president of Nu Skin and leadership positions in consumer products within Johnson & Johnson.




							Debora Jorn


					
							Ms. Debora Jorn is Director of the Company. She has extensive experience in building multi-billion dollar U.S. and global life science businesses. She has a proven record of designing and implementing innovative business and marketing strategies that have delivered double digit organic growth across numerous therapeutic areas. Most recently Ms. Jorn served as executive vice president and company group chair at Valeant, chief global marketing officer at Bausch & Lomb, and group vice president for women's health and fertility at Schering Plough.




							Arlene Morris


					
							Ms. Arlene M. Morris is Director of the Company. She joins the board with significant life science experience in the development of strategic partnerships and transactions, global marketing, product pipeline development and operations. She has served as president and chief executive officer of Syndax Pharmaceuticals and has held executive leadership positions at Johnson & Johnson's Ortho-McNeil Pharmaceutical, Scios, Coulter Pharmaceuticals, Clearview Projects, and Affymax.




							Jon Plexico


					
							Mr. Jon M. Plexico is Director of the Company. Mr. Plexico is currently a managing member of Stonepine Capital Management, LLC. Previously, Mr. Plexico was managing director at Merriman Curhan Ford & Co., where he ran the healthcare corporate finance division focusing on private investments in public equity (PIPEs), secondary offerings, and mergers and acquisitions. Prior to that, Mr. Plexico was co-founding partner of Venture Ready Partners, a life science advisor providing capital raising services to private biotechnology companies. Mr. Plexico served as director of business development at Chemdex Corporation, an electronic life-science commerce company that completed an initial public offering during his tenure. He began his career at Quidel Corporation, where he became national sales manager for the autoimmune division. Mr. Plexico is a graduate of Colgate University.




							Daniel Janney


					
							Mr. Daniel S. Janney is Independent Director of Viveve Medical, Inc. Mr. Janney was elected as a director of Viveve Medical, Inc. on September 18, 2014 (with his service beginning following the Merger). Since November 2012, Mr. Janney has served as a director of Esperion Therapeutics, Inc. (NASDAQ: ESPR). Mr. Janney is a managing director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, from 1993 to 1996, he was a Vice President in Montgomery Securities' healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of a number of companies including Alba Therapeutics Corporation, Lithera, Inc., Prolacta Bioscience, Inc., Sutro Biopharma and ViroBay, Inc. He holds a Bachelor of Arts in History from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Because of Mr. Janney's experience working with and serving on the boards of directors of life sciences companies and his experience working in the venture capital industry, we concluded that he should serve as a director.











					Basic Compensation





Name
Fiscal Year Total




							James Atkinson

--




							Patricia Scheller

652,264




							Scott Durbin

486,583




							Alan Curtis

241,466




							Steve Lopez

--




							Lori Bush

--




							Debora Jorn

--




							Arlene Morris

--




							Jon Plexico

--




							Daniel Janney

--



As Of 
30 Dec 2014





					Options Compensation





Name
Options
Value




							James Atkinson

0
0




							Patricia Scheller

0
0




							Scott Durbin

0
0




							Alan Curtis

0
0




							Steve Lopez

0
0




							Lori Bush

0
0




							Debora Jorn

0
0




							Arlene Morris

0
0




							Jon Plexico

0
0




							Daniel Janney

0
0









					Insider Trading












Name
Shares Traded
Price


Jorn (Debora A)
686
$0.00


Janney (Daniel Spencer)
2,387
$0.00


Plexico (Jon M)
1,592
$0.00


Stonepine Capital, L.P.
1,250,000
$4.00


Atkinson (James G)
187,500
$4.00


Janney (Daniel Spencer)
500,000
$4.00


Atkinson (James G)
187,500
$4.00


Scheller (Patricia)
12,500
$4.00


Jorn (Debora A)
1,109
$0.00


Bush (Lori H)
1,109
$0.00


Morris Arlene M
1,442
$0.00


Janney (Daniel Spencer)
1,775
$0.00


Plexico (Jon M)
1,109
$0.00


Jorn (Debora A)
800
$0.00


Bush (Lori H)
800
$0.00


Plexico (Jon M)
800
$0.00


Morris Arlene M
1,040
$0.00


SMITH BRIGITTE
1,279
$0.00


Janney (Daniel Spencer)
1,279
$0.00


Atkinson (James G)
100,000
$5.00


Scheller (Patricia)
6,000
$5.00


Stonepine Capital, L.P.
300,000
$5.00


Durbin (Scott C)
1,500
$5.00


Janney (Daniel Spencer)
200,000
$5.00


Scheller (Patricia)
588
$0.85




» Full list on Insider Trading
















Related Topics: 
StocksStock ScreenerMarket DataHealthcareAdvanced Medical Equipment & Technology






























Debora Jorn - Valeant Pharma Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsDebora JornValeant Pharma (VRX)EVP, Company Group Chairman Not RankedDebora Jorn's PerformanceDebora Jorn has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Insider Holdings 100.0% Valeant Pharma (VRX)$605KSee the Top Stocks by Insiders > Insider RolesValeant Pharma (VRX): EVP, Company Group ChairmanSee the Top 25 Corporate Insiders > Debora Jorn's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateVRXValeant PharmaEVP, Company Group Chairman$604,601Uninformative Sell$0Nov 24, 2015OREXOrexigenDirector-PSDVpSividaEVP, Corp. & Comm'l Dev.-See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























